Ibex Investors’s Neurocrine Biosciences NBIX Stock Holding History

Ibex Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,705	Closed	-$210K	–	218
2018 Q3	$210K	Buy	+1,705	New	+$193K	0.12%	110
2018 Q1	–	Sell	-3,352	Closed	-$263K	–	235
2017 Q4	$263K	Buy	+3,352	New	+$229K	0.15%	96

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ibex Investors's NBIX Position: Q4 2018 in Review

Ibex Investors sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 1,705 shares — an estimated $210K sold.

Ibex Investors first reported a position in NBIX in Q4 2017 and held it in 2 quarters. The position peaked at $263K in Q4 2017. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Ibex Investors reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Ibex Investors sold 1,705 Neurocrine Biosciences shares in Q4 2018, an estimated $210K.
Ibex Investors first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 2 quarters.
Ibex Investors's Neurocrine Biosciences position peaked at $263K in Q4 2017.
330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Ibex Investors's 13F filing for Q4 2018, filed 13 Feb 2019.